ArticleFrontiers in microbiology2026
A novel bacteriophage capable of efficiently lysing multi-drug-resistant
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The increasing prevalence of carbapenem-resistant Methods: A novel Klebsiella pneumoniae phage was isolated and purified from hospital wastewater using the double-layer agar plate method with Results: The novel phage vB_KpnD_A2 exhibited potent lytic activity against multidrug-resistant Klebsiella pneumoniae strains. Host range analysis showed that vB_KpnD_A2 lysed 57.1% of carbapenem-resistant K. pneumoniae isolates and 63.6% of extended-spectrum β-lactamase-producing strains, while displaying specificity toward Discussion: The newly characterized phage vB_KpnD_A2 exhibited potent lytic activity against selected multidrug-resistant Klebsiella pneumoniae isolates, favorable genomic safety, and good environmental stability. These findings support its potential as a therapeutic phage candidate for CRKP control and expand anti-Klebsiella phage resources for future phage-based interventions against antimicrobial-resistant bacterial infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.